[Immunoglobulin Replacement Therapy in Antibody Production Defects]

Area of Science:

• Immunology
• Clinical Medicine
• Pharmacology

Background:

• Inborn errors of immunity (IEI) often impair humoral response, necessitating immunoglobulin replacement therapy (IRT).
• IRT provides passive immunity, crucial for preventing infections and long-term complications in affected individuals.
• Current IRT administration routes include intravenous (IVIG), conventional subcutaneous (SCIG), and facilitated subcutaneous (SCIG-H) using recombinant hyaluronidase.

Purpose of the Study:

• To clarify available immunoglobulin treatment modalities for patients with IEI.
• To provide practical guidance for selecting the optimal IRT administration route.
• To enhance patient adherence and treatment effectiveness, improving clinical stability.

Main Methods:

• Review of current immunoglobulin administration routes: IVIG, SCIG, and SCIG-H.
• Analysis of advantages and limitations associated with each administration route.
• Emphasis on individualized treatment selection involving patient participation and healthcare professional guidance.

Main Results:

• Individualized selection of IRT route is essential for optimal outcomes.
• Patient-centered decision-making, considering route-specific benefits and drawbacks, improves adherence.
• Facilitated subcutaneous immunoglobulin offers an alternative administration option.

Conclusions:

• Optimizing immunoglobulin replacement therapy requires a personalized approach to route selection.
• Active patient involvement and expert guidance are critical for successful IRT.
• Improved adherence and route selection contribute to enhanced clinical stability in patients with IEI.